JGH open : an open access journal of gastroenterology and hepatology · 2025
Cemiplimab-Induced Colitis Causing Hypovolemic Shock: A Case Report and Literature Review.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Graham Saeed S, Lemu Kena J, Thomas Victoria Mofopefoluwa, Oghoghorie Stanley O, Swaiti Abdulazeez R, Liu Jinye, Faheem Alina
Аннотация
INTRODUCTION: The use of immune checkpoint inhibitors (ICI), such as Cemiplimab, has become prevalent in oncology, providing significant anti-tumor effects. However, these agents can induce severe gastrointestinal inflammation, which may be potentially life-threatening. This case report details an instance of Cemiplimab-induced colitis resulting in hypovolemic shock in a patient with cutaneous squamous cell carcinoma (cSCC).
CASE PRESENTATION: An 83-year-old male veteran with a complex history of scalp squamous cell carcinoma, treated initially with excision and radiation, experienced recurrence necessitating Cemiplimab therapy. One year post-initiation, the patient presented with severe diarrhea, leading to hypovolemic shock and acute renal failure. Initial tests ruled out infectious causes. Endoscopic evaluation revealed inflammatory mucosal changes in the sigmoid colon, and histopathology confirmed active colitis. The patient responded well to high-dose prednisone, with rapid improvement in symptoms, leading to a transfer to a lower level of care.
CONCLUSION: Cemiplimab, approved for advanced cSCC, fulfills a crucial therapeutic need but is associated with immune-related adverse events, including severe colitis. Management of such cases requires early endoscopy and corticosteroid therapy, which can significantly improve outcomes. This report underscores the importance of vigilant monitoring for gastrointestinal symptoms in patients undergoing ICI therapy and prompt intervention to mitigate severe complications.
CASE PRESENTATION: An 83-year-old male veteran with a complex history of scalp squamous cell carcinoma, treated initially with excision and radiation, experienced recurrence necessitating Cemiplimab therapy. One year post-initiation, the patient presented with severe diarrhea, leading to hypovolemic shock and acute renal failure. Initial tests ruled out infectious causes. Endoscopic evaluation revealed inflammatory mucosal changes in the sigmoid colon, and histopathology confirmed active colitis. The patient responded well to high-dose prednisone, with rapid improvement in symptoms, leading to a transfer to a lower level of care.
CONCLUSION: Cemiplimab, approved for advanced cSCC, fulfills a crucial therapeutic need but is associated with immune-related adverse events, including severe colitis. Management of such cases requires early endoscopy and corticosteroid therapy, which can significantly improve outcomes. This report underscores the importance of vigilant monitoring for gastrointestinal symptoms in patients undergoing ICI therapy and prompt intervention to mitigate severe complications.